Rimonabant [clinicaltrials_resource:4bd703b2af08143014e1c820b0766c7f]
Rimonabant to Reduce Alcohol Consumption [clinicaltrials:NCT00075205]STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study) [clinicaltrials:NCT00124332]clinicaltrials:NCT00228176An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients [clinicaltrials:NCT00239967]Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients [clinicaltrials:NCT00257257]clinicaltrials:NCT00263042Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO) [clinicaltrials:NCT00288236]VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt [clinicaltrials:NCT00299325]Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA) [clinicaltrials:NCT00325546]Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes (RAPSODI) [clinicaltrials:NCT00325650]Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US) [clinicaltrials:NCT00358228]Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe) [clinicaltrials:NCT00386061]Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose [clinicaltrials:NCT00405808]High Density Lipoprotein Turnover [clinicaltrials:NCT00408148]European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia [clinicaltrials:NCT00412698]Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) [clinicaltrials:NCT00434096]clinicaltrials:NCT00449605Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors [clinicaltrials:NCT00458081]Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch [clinicaltrials:NCT00458718]Japanese Dose-Response Study of Rimonabant in Obese Patients [clinicaltrials:NCT00459004]Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation [clinicaltrials:NCT00459173]Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation [clinicaltrials:NCT00464165]Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation [clinicaltrials:NCT00464256]clinicaltrials:NCT00478595clinicaltrials:NCT00478972Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients [clinicaltrials:NCT00481923]Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients [clinicaltrials:NCT00481975]Interaction Between Rimonabant and Cyclosporine and Tacrolimus [clinicaltrials:NCT00525681]REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents [clinicaltrials:NCT00546325]clinicaltrials:NCT00547118clinicaltrials:NCT00576667clinicaltrials:NCT00577148clinicaltrials:NCT00584389clinicaltrials:NCT00603109Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque [clinicaltrials:NCT00636766]clinicaltrials:NCT00656487clinicaltrials:NCT00678483clinicaltrials:NCT00690456clinicaltrials:NCT00734123Antagonistic Interaction CB1-paracetamol [clinicaltrials:NCT00750347]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Rimonabant [clinicaltrials_resource:4bd703b2af08143014e1c820b0766c7f]
Bio2RDF identifier
4bd703b2af08143014e1c820b0766c7f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4bd703b2af08143014e1c820b0766c7f
identifier
clinicaltrials_resource:4bd703b2af08143014e1c820b0766c7f
title
Rimonabant
@en
type
label
Rimonabant [clinicaltrials_resource:4bd703b2af08143014e1c820b0766c7f]
@en